Table 2. Leishmanin skin test (LST) reactivity, mean IFN-γ, IL-4 and IL-10 levels in the study volunteers.

Leishmanin skin test induration/mm IFN—γ/pcm/ml IL-4 pcm/ml IL10
LST non-reactive (00mm)(n = 12):
Control (No antigens/peptides) 239 ± 251 (133) 26 ± 32 (16) 993 ± 693 (681)
Soluble Leishmania antigen 183 ± 126 (222) 18 ± 22 (14) 947 ± 445 (1004)
P1 peptide 199 ± 259 (139) 25 ± 30 (17) 1085 ± 651 (1210)
P2 peptide 187 ± 222 (128) 25 ± 31 (18) 1095 ± 590 (1271)
P3 peptide 214 ± 261 (132) 26 ± 28 (16) 1958 ± 489 (940)*
P4 peptide 253 ± 345 (180) 23 ± 28 (17) 824 ± 716 (510)

LST-reactive (≥ 8 mm)(n = 10):
Control (No antigens/peptides) 52 ± 76 (14) 05 ± 10 (1) 624 ± 337 (740)
Soluble Leishmania antigen 169 ± 397(31) 08 ± 10 (6) 683 ± 429 (573)
P1 peptide 40 ± 67 (12) 09 ± 12 (5) 1339 ± 706 (1430)*
P2 peptide 40 ± 60 (15) 13 ± 18 (3) 754 ± 422 (727)
P3 peptide 37 ± 54 (13) 12 ± 16 (4) 698 ± 481 (701)
P4 peptide 58 ± 82 (24) 10 ± 12 (7) 208 ± 369 (102)**

Continuous variables are expressed as mean ± SD (median). pcm/ml = picogram/ml. P1, P2, P3 and P4 the predicted and synthesized peptides. * p = 0.0097 **p = 0.016